Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 19

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
Item 1. Condensed Consolidated Financial Statements (Unaudited)

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

September 30,2025December 31,2024(unaudited)AssetsCurrent assetsCash and cash equivalents$23,075,261 $15,698,174 Other receivables369,157 229,982 Prepaid expenses1,506,603 2,519,707 Other current assets53,159 — Total current assets25,004,180 18,447,863 Property and equipment, net1,657,255 1,335,732 Operating lease right-of-use assets824,693 1,206,942 Finance lease right-of-use asset2,244,073 — Other non-current assets1,018,373 1,110,594 Total assets$30,748,574 $22,101,131 Liabilities and stockholders’ equity (deficit)Current liabilitiesAccounts payable$1,844,862 $1,455,832 Accrued expenses2,324,931 3,042,918 Deferred grant funding14,557,265 16,561,625 Current portion of liability related to the sale of future royalties10,542 4,054 Current portion of lease liabilities, operating609,224 548,638 Current portion of lease liability, finance1,869,570 — Total current liabilities21,216,394 21,613,067 Deferred revenue, non-current1,000,000 1,000,000 Liability related to the sale of future royalties, net5,220,525 4,745,770 Lease liabilities long-term, operating288,566 754,383 Lease liability long-term, finance165,186 — Total liabilities27,890,671 28,113,220 Commitments and contingencies (Note 9)Stockholders' equity (deficit)Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding— — Common stock, $0.0001 par value; 240,000,000 shares authorized; 13,929,502 and 8,700,386 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively1,393